Cargando…

CHEK2 1100 delC mutation in Russian ovarian cancer patients

BRCA1 and BRCA2 germ-line mutations occur in a significant number of unselected ovarian cancer (OC) patients, thus making a noticeable contribution to OC morbidity. It is of interest whether CHEK2, which is frequently regarded as a third breast cancer specific gene, is also relevant to ovarian cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krylova, Nadezhda Yu, Ponomariova, Daria N, Sherina, Natalia Yu, Ogorodnikova, Natalia Yu, Logvinov, Denis A, Porhanova, Natalia V, Lobeiko, Oksana S, Urmancheyeva, Adel F, Maximov, Sergey Ya, Togo, Alexandr V, Suspitsin, Evgeny N, Imyanitov, Evgeny N
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736987/ https://www.ncbi.nlm.nih.gov/pubmed/19725991 http://dx.doi.org/10.1186/1897-4287-5-3-153

Ejemplares similares

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
por: Suspitsin, Evgeny N, et al.
Publicado: (2009)

BRCA1 4153delA founder mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2006)

CHEK2 (∗)1100delC Mutation and Risk of Prostate Cancer
por: Hale, Victoria, et al.
Publicado: (2014)

The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis
por: Koppert, L B, et al.
Publicado: (2004)

CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum
por: Isinger, Anna, et al.
Publicado: (2006)

Genomic profiling of CHEK2*1100delC-mutated breast carcinomas
por: Massink, Maarten P. G., et al.
Publicado: (2015)

Genetic modifiers of CHEK2*1100delC associated breast cancer risk
por: Muranen, Taru A., et al.
Publicado: (2016)

CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer
por: Margolin, Sara, et al.
Publicado: (2007)

Frequency of CHEK2*1100delC in New York breast cancer cases and controls
por: Offit, Kenneth, et al.
Publicado: (2003)

A Case of Male Breast Cancer Patient with CHEK2*1100delC Mutation
por: Nguyen, Quan D, et al.
Publicado: (2020)

Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families
por: Cierniková, S, et al.
Publicado: (2005)

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers
por: Kriege, Mieke, et al.
Publicado: (2015)

Risk for contralateral breast cancer among carriers of the CHEK2(*)1100delC mutation in the WECARE Study
por: Mellemkjær, L, et al.
Publicado: (2008)

Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications
por: Muranen, Taru A, et al.
Publicado: (2011)

Frequency of the CHEK2 1100delC mutation among women with early-onset and bilateral breast cancer
por: Ding, Dapeng, et al.
Publicado: (2012)

Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer
por: Woodward, Emma R., et al.
Publicado: (2021)

A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients
por: Wendt, Camilla, et al.
Publicado: (2021)

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
por: Kriege, M, et al.
Publicado: (2014)

The CHEK2 1100delC allelic variant is not present in familial and sporadic breast cancer cases from Moroccan population
por: Marouf, Chaymaa, et al.
Publicado: (2015)

CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population
por: Hallamies, Sanna, et al.
Publicado: (2017)

Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals
por: Jekimovs, C R, et al.
Publicado: (2005)

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival
por: Morra, Anna, et al.
Publicado: (2023)

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
por: Morra, Anna, et al.
Publicado: (2023)

BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer
por: Francies, F. Z., et al.
Publicado: (2015)

Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma
por: Thibodeau, My Linh, et al.
Publicado: (2017)

Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile
por: Smid, Marcel, et al.
Publicado: (2023)

Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk
por: Varley, Jenny, et al.
Publicado: (2003)

Hereditary Breast-Ovarian Cancer Syndrome in Russia
por: Sokolenko, A.P., et al.
Publicado: (2010)

Corrigendum: Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma
por: Thibodeau, My Linh, et al.
Publicado: (2018)

Hereditary cancer syndromes
por: Imyanitov, Evgeny N, et al.
Publicado: (2023)

Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing
por: Sokolenko, Anna P, et al.
Publicado: (2009)

CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II
por: Lopez, Santiago J., et al.
Publicado: (2023)

The checkpointkinase 2 (CHK2) 1100delC germ line mutation is not associated with the development of squamous cell carcinoma of the head and neck (SCCHN)
por: Scheckenbach, Kathrin, et al.
Publicado: (2010)

Revisiting multiple erroneous genetic testing results and clinical misinterpretations in a patient with Li-Fraumeni syndrome: lessons for translational medicine
por: Sokolova, Tatiana N., et al.
Publicado: (2021)

Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1
por: Imyanitov, Evgeny N., et al.
Publicado: (2020)

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study
por: Orlov, Sergey V., et al.
Publicado: (2021)

PALB2 mutations in German and Russian patients with bilateral breast cancer
por: Bogdanova, Natalia, et al.
Publicado: (2010)

Targeted exome analysis of Russian patients with hypertrophic cardiomyopathy
por: Filatova, Elena V., et al.
Publicado: (2021)

Preparation of Duplex Sequencing Libraries for Archival Paraffin-Embedded Tissue Samples Using Single-Strand-Specific Nuclease P1
por: Mitiushkina, Natalia V., et al.
Publicado: (2022)

Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?
por: Imyanitov, Evgeny N
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ssvj1mf5hj4s7relqt0am4s47b